Eli Lilly and Co (BUE:LLY) Net Interest Margin (Bank Only) %


BUE:LLY Eli Lilly and Co BUE:LLY
97 GF Score
Price ARS34,740.00
GF Value ARS40,551.80
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Eli Lilly and Co Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

BUE:LLY
97GF Score
Eli Lilly and Co BUE:LLY
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eli Lilly and Co (BUE:LLY) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be undervalued. The current stock price of ARS34,740.00 is trading 14.3% below its estimated GF Value™ of ARS40,551.80. GuruFocus considers Eli Lilly and Co to be Modestly Undervalued.

Key valuation signals for BUE:LLY:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: ARS40,551.80 vs. price of ARS34,740.00 (14.3% below fair value)
  • GF Score™: 97/100 with 6 warning signs

No single metric tells the full story. See the BUE:LLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
97GF Score

Get the complete analysis for BUE:LLY

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS34,740.00
Price
ARS40,551.80
GF Value